Expression of eIF6 and its relationship with cell proliferation in colorectal adenocarcinoma

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

Objectives

Eukaryotic translation initiation factors (eIFs) are genes related to tumor formation. They selectively translate some mRNAs, regulate protein synthesis, promote cell proliferation, and effectively control the progression of some tumors. As a member of this family, eukaryotic translation initiation factor 6 (eIF6) plays a crucial role in tumor formation and progression. Exploring the expression characteristics of eIF6 and proliferating cell nuclear antigen (PCNA), a proliferation-associated factor, in colorectal adenocarcinoma (CRAC) and analyzing their correlation and clinical significance can provide a theoretical basis for the study of CRAC and objective biological indicators for the clinical judgment of tumor formation and progression.

Methods

The GEPIA database was used to predict the trend of eIF6 and PCNA in CRAC. Sixty-four patients diagnosed with CRAC and undergoing surgical treatment were selected from January 2017 to November 2022. CRAC tissues and normal mucous tissues (>3 cm away from the tumor margin) were retained. The expression of eIF6 and PCNA was detected by immunohistochemistry (IHC). Colon cancer cell lines SW480, HCT15, and SW620 and normal colon cell line NCM460 were selected, and the expression of eFI6 and PCNA in these cells was detected by Western blot.

Results

A trend of elevated expression of eIF6 and PCNA was predicted in CRAC by the GEPIA database. The expression levels of eIF6 (65.63 % vs. 9.38 %, X ²=43.2000, p<0.0001) and PCNA (84.38 % vs. 46.88 %, X ²=19.9481, p<0.0001) were higher in CRAC tissues than that in normal mucosa as indicated by IHC. Significant difference in eIF6 and PCNA expression was found among different maxim tumor diameters and depths of infiltration in colon adenocarcinoma (p<0.05). No statistical difference in eIF6 and PCNA expression was observed among different genders, ages, degrees of differentiation, LNMets, intravascular cancer thrombosis, TNM stages, and numbers of lymph node metastases (p>0.05). A positive correlation was found between eIF6 and PCNA in CRAC (X ²=5.05, r=0.77, p=0.0283). Their expression was significantly higher in SW480, HCT15, and SW620 than in NCM460 (p<0.05).

Conclusions

eIF6 is highly expressed in CRAC, participates in tumor formation and progression, and has a positive correlation with PCNA.

Related collections

Most cited references 25

Record: found
Abstract: found
Article: not found

Signalling to eIF4E in cancer

Nadeem Siddiqui, Nahum Sonenberg (2015)

Translational control plays a critical role in the regulation of gene expression in eukaryotes and affects many essential cellular processes, including proliferation, apoptosis and differentiation. Under most circumstances, translational control occurs at the initiation step at which the ribosome is recruited to the mRNA. The eukaryotic translation initiation factor 4E (eIF4E), as part of the eIF4F complex, interacts first with the mRNA and facilitates the recruitment of the 40S ribosomal subunit. The activity of eIF4E is regulated at many levels, most profoundly by two major signalling pathways: PI3K (phosphoinositide 3-kinase)/Akt (also known and Protein Kinase B, PKB)/mTOR (mechanistic/mammalian target of rapamycin) and Ras (rat sarcoma)/MAPK (mitogen-activated protein kinase)/Mnk (MAPK-interacting kinases). mTOR directly phosphorylates the 4E-BPs (eIF4E-binding proteins), which are inhibitors of eIF4E, to relieve translational suppression, whereas Mnk phosphorylates eIF4E to stimulate translation. Hyperactivation of these pathways occurs in the majority of cancers, which results in increased eIF4E activity. Thus, translational control via eIF4E acts as a convergence point for hyperactive signalling pathways to promote tumorigenesis. Consequently, recent works have aimed to target these pathways and ultimately the translational machinery for cancer therapy.